References
- Michel MS, Vervenne W, de Santis M, et al. SWITCH: a randomized sequential open-label study to evaluate efficacy and safety of sorafenib (SO)/sunitinib (SU) versus SU/SO in the treatment of metastatic renal cell cancer (mRCC). J Clin Oncol 2014;32(Suppl 4): abstract 393
- Motzer RJ, Barrios CH, Kim TM, et al. Record-3: phase II randomized trial comparing sequential first-line everolimus (EVE) and second-line sunitinib (SUN) versus first-line SUN and second-line EVE in patients with metastatic renal cell carcinoma (mRCC). J Clin Oncol 2013;31(Suppl): abstract 4504
- Davis ID, Long A, Martin A, et al. EVERSUN: a phase II trial of everolimus alternating with sunitinib as first-line therapy for advanced renal cell carcinoma (aRCC) (ANZUP trial 0901). J Clin Oncol 2014;32(Suppl 4): abstract 438
- Bracarda S, Iacovelli R, Rizzo M, et al. Retrospective observational study of sunitinib administered on schedule 2/1 in patients with metastatic renal cell carcinoma (mRCC): The rainbow study. J Clin Oncol 2014;32(Suppl 4): abstract 471
- Ray-Coquard IL, Janus N, Goldwasser F, et al. Results of the MARS study on the management of antiangiogenics’ renovascular safety in renal cell carcinoma. J Clin Oncol 2014;32(Suppl 4): abstract 394
- Beer TM, Armstrong AJ, Sternberg CN, et al. Enzalutamide in men with chemotherapy-naive metastatic prostate cancer (mCRPC): Results of phase III PREVAIL study. J Clin Oncol 2014;32(Suppl 4): abstract LBA1
- Ryan CJ, Smith MR, de Bono JS, et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med 2013;368:138-48
- Basch E, Autio K, Ryan CJ, et al. Abiraterone acetate plus prednisone versus prednisone alone in chemotherapy-naive men with metastatic castration-resistant prostate cancer: patient-reported outcome results of a randomised phase 3 trial. Lancet Oncol 2013;14:1193-9
- Dreicer R, Jones R, Oudard S, et al. Results from a phase 3, randomized, double-blind, multicenter, placebo-controlled trial of orteronel (TAK-700) plus prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC) that has progressed during or following docetaxel-based therapy (ELM-PC 5 trial). J Clin Oncol 2014;32(Suppl 4): abstract 7
- Gerritsen WR, Kwon ED, Fizazi K, et al. CA 184-043: a randomized, multicenter, double-blind phase 3 trial comparing overall survival (OS) in patients (pts) with post-docetaxel castration-resistant prostate cancer (CRPC) and bone metastases treated with ipilimumab (ipi) vs placebo (pbo), each following single-dose radiotherapy (RT). European Cancer Congress 2013. Abstract 2850
- Drake CG, Kwon ED, Fizazi K, et al. Results of subset analyses on overall survival (OS) from study CA184-043: Ipilimumab (Ipi) versus placebo (Pbo) in post-docetaxel metastatic castration-resistant prostate cancer (mCRPC). J Clin Oncol 2014;32(Suppl 4): abstract 2
- Pell RJ, Harland SJ. The natural history of bone metastases in castrate-resistant prostate cancer. J Clin Oncol 2014;32(Suppl 4): abstract 239